Markets:

Overview

News

Currencies

International

Treasuries

10x Genomics, Inc. - Common Stock (NQ:TXG)

48.03 +0.98 (+2.09%)

Streaming Delayed Price Updated: 12:13 PM EDT, Jul 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about 10x Genomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

3 Reasons to Sell TXG and 1 Stock to Buy Instead

March 20, 2026

10x Genomics has had an impressive run over the past six months. While the S&P 500 has been flat, the stock has returned 39.8% and now trades at $18.24. This...

Via StockStory

Topics Stocks Supply Chain

1 Cash-Producing Stock with Competitive Advantages and 2 We Ignore

March 16, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...

Via StockStory

3 Healthcare Stocks We’re Skeptical Of

March 13, 2026

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...

Via StockStory

3 Russell 2000 Stocks We Approach with Caution

March 10, 2026

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...

Via StockStory

Topics Retirement

10X Genomics (NASDAQ:TXG) Posts Q4 Earnings Beat Amid Cautious 2026 Outlook ↗

February 12, 2026

Via Chartmill

Topics Earnings

Life Sciences Tools & Services Stocks Q4 In Review: 10x Genomics (NASDAQ:TXG) Vs Peers

March 05, 2026

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the life sciences tools & services stocks, including 10x Genomics (NASDAQ:TXG) and its ...

Via StockStory

Topics Artificial Intelligence

The "Flight to Quality": Thermo Fisher’s Q4 Beat and Dividend Hike Cement Defensive Leadership for 2026

February 27, 2026

WALTHAM, MA — In a market defined by shifting geopolitical alliances and a renewed "flight to quality," Thermo Fisher Scientific (NYSE:TMO) has once again asserted its dominance as the bedrock of the...

Via MarketMinute

Topics Earnings Economy World Trade

3 Stocks Under $50 We’re Skeptical Of

February 26, 2026

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to...

Via StockStory

Topics Artificial Intelligence

5 Must-Read Analyst Questions From 10x Genomics’s Q4 Earnings Call

February 19, 2026

10x Genomics’ fourth quarter results saw stable revenue performance despite a subdued research funding environment, with management crediting continued consumables growth and increased adoption of new...

Via StockStory

Topics Earnings

3 Volatile Stocks We Steer Clear Of

February 15, 2026

A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared.

Via StockStory

Why Is 10x Genomics (TXG) Stock Soaring Today

February 13, 2026

Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 10.5% in the morning session after the company reported better-than-expected fourth-quarter results, highlighted by a smaller loss than...

Via StockStory

Topics Government World Trade

TXG Q4 Deep Dive: Consumables Growth, Spatial Expansion, and AI-Driven Demand Shape Outlook

February 13, 2026

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2025 results exceeding the market’s revenue expectations, but sales were flat year on year at $166 million. The company expects the full year’s...

Via StockStory

Topics Artificial Intelligence

10x Genomics (TXG) Q4 2025 Earnings Transcript ↗

February 12, 2026

10x Genomics (TXG) Q4 2025 Earnings Transcript

Via The Motley Fool

Topics Intellectual Property

10x Genomics (NASDAQ:TXG) Delivers Impressive Q4 CY2025

February 12, 2026

Biotech company 10x Genomics (NASDAQ:TXG) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, but sales were flat year on year at $166 million. The company expects the full year’s...

Via StockStory

10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect

February 10, 2026

Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings this Thursday after market hours. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence World Trade

1 Momentum Stock to Target This Week and 2 We Turn Down

February 02, 2026

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro...

Via StockStory

3 Small-Cap Stocks We’re Skeptical Of

January 25, 2026

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...

Via StockStory

3 Cash-Producing Stocks That Fall Short

January 22, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

3 Unprofitable Stocks with Warning Signs

January 21, 2026

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital...

Via StockStory

Life Sciences Tools & Services Stocks Q3 Teardown: Illumina (NASDAQ:ILMN) Vs The Rest

January 21, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Illumina (NASDAQ:ILMN) and its peers.

Via StockStory

Topics Artificial Intelligence

3 Hyped Up Stocks That Concern Us

January 18, 2026

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial...

Via StockStory

1 Healthcare Stock to Consider Right Now and 2 We Find Risky

January 15, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and...

Via StockStory

Topics Stocks

1 Cash-Heavy Stock to Consider Right Now and 2 We Question

January 12, 2026

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Via StockStory

Why 10x Genomics (TXG) Shares Are Falling Today

January 12, 2026

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 4.7% in the afternoon session after the company announced weak preliminary results for its fourth quarter and full year 2025, which pointed to a...

Via StockStory

Topics Intellectual Property

CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response

January 07, 2026

From CareDx, Inc.

Via Business Wire

10x Genomics (TXG) Stock Is Up, What You Need To Know

January 02, 2026

Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 2.5% in the afternoon session after several analysts raised their price targets on the stock, pointing to a more optimistic outlook for the...

Via StockStory

Topics Artificial Intelligence

2 Russell 2000 Stocks Worth Investigating and 1 We Avoid

January 01, 2026

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher...

Via StockStory

10x Genomics (TXG) Stock Trades Up, Here Is Why

December 22, 2025

Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 4.8% in the morning session after Canaccord Genuity maintained its 'Buy' rating and raised its price target on the company's shares.

Via StockStory

Topics Artificial Intelligence

1 Stock Under $50 Worth Your Attention and 2 We Turn Down

December 21, 2025

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and...

Via StockStory

10x Genomics (TXG) Q2 2025 Earnings Transcript ↗

December 11, 2025

10x Genomics (TXG) Q2 2025 Earnings Transcript

Via The Motley Fool

Topics Intellectual Property World Trade

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.